Live Breaking News & Updates on Sheffield University Medical School|Page 2

Share:
MONT-SAINT-GUIBERT, Belgium, April 19, 2021 (GLOBE NEWSWIRE) Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced the appointment of Dr. Charles Morris to the position of Chief Medical Officer. Dr. Morris will lead and provide strategic direction for all medical, regulatory and clinical development activities.
We are delighted to bring someone with Dr. Morris s vast expertise and experience on board during this pivotal time in the Company, said Filippo Petti, CEO of Celyad Oncology. Dr. Morris has played an integral part in guiding multiple late-stage oncology drugs to approval and his demonstrated track record of leadership in the pharmaceutical industry will greatly benefit the work we are doing at Celyad Oncology. ....

United Kingdom , City Of , Sara Zelkovic , Filippo Petti , Charles Morris , Communications Investor Relations , Allos Therapeutics , Lifesci Advisors , Worldwide Clinical Research At Cephalon Inc , Exchange Commission , Radius Health , Sheffield University Medical School , Immunogen Inc , Chief Medical , Celyad Oncology , Chief Medical Officer , Psioxus Therapeutics , Vice President , Worldwide Clinical Research , Medical Science , Clinical Pharmacology , Royal College , Private Securities Litigation Reform Act , Annual Report , Media Contacts , Sci Advisors ,